The drugmaker recently completed its $39-billion acquisition of Alexion, which it had agreed to buy as a bet on rare-disease immunology and to boost its business that includes a fast-growing cancer medicines unit and a major COVID-19 vaccine.from International-News-Economic Times https://ift.tt/3zzjHDZ
via IFTTT
0 comments:
Post a Comment